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1. Introduction 
Despite the current knowledge, the mechanisms by which the specific immunotherapy 
(SIT) achieves clinical improvement remains unclear. However, it is now clear that the 
immune tolerance is one of the major targets of this kind of treatment. Immune tolerance 
depends on different mechanisms, including T-cell anergy, T-cell depletion by apoptosis, 
and active immune suppression (Akdis & Akdis, 2011). One of the goals of SIT is the 
induction of tolerance to allergens to which the patient is sensitized. IL-10 is probably a 
relevant cytokine induced by this treatment and is associated to regulatory T cells (T-regs) 
that actively control or suppress the function of other cells, generally in an inhibitory 
pattern (Frew, 2010).  
The changes in microenvironment due to the decrease in histamine and PGE2 release by mast 
cell, and the IL-10 and TGF- release by dendritic cells (DC) could switch the T-cell population 
into T-regs. These alterations will then lead to tolerance (Schmidt-Weber & Blaser 2005).  
Much of the knowledge about SIT has been based on studies using subcutaneous route of 
administration (SCIT), but increasing data is now available based on studies using 
sublingual immunotherapy (SLIT).  
The sublingual mucosa, where the deposition of the extract occurs, has very particular 
characteristics, quite different from the cellular subcutaneous tissue. The dendritic cells 
present in the buccal region are distinct from the Langerhans cells present in the skin. These 
cells present, constitutively, receptors with high affinity for IgE, FcRI+, MHC class I and II 
molecules, as well as co-stimulation molecules, namely CD40, CD80/B7.1 and CD86/B7.2 
(Allam et al., 2006). There is also expression of CD14, a lipopolysaccharide (LPS) receptor, 
which is relevant for the modulation of Th2 and Th1. 
In SLIT, the allergen is captured by the DC cell by C-lectin endocytosis receptors and/or by 
ligation to the IgE on the surface. After the internalization, the migration to the regional 
lymphoid nodules occurs, and it is then presented to the T cells (Geijtenbeek, 2006). A study 
that compares the DC population in the oral and nasal mucosa was able to demonstrate that 
only the DC myeloid type is profusely present in the oral region, in contrast with the nasal 
mucosa where both populations are present (Allam et al., 2006). Another very important 
difference is the high expression levels of FcRI in the oral mucosa, which is almost absent in 
the skin’s Langerhans cells (Allam et al., 2003). Furthermore, the expression levels of MHC 
class I and II molecules, CD40, CD80 and CD86 is significantly higher in oral DC than in the 
skin. 
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The integrity of the lamina propria in the oral mucosa, along with the highly reduced 
population of mast cells, eosinophils and basophils, are the factors that limit the contact of 
the allergen with submucosal areas or with circulating blood cells. All of these together 
constitute the excellent security profile characteristic of the SLIT (Moingeon et al., 2006). The 
DC seems to be crucial in the induction of the tolerance profile due to the production of IL-
10 and TGF- after activation, as well as an increase in indoleamine dioxygenase type 2 
(IDO), necessary to the decrease in T cells proliferation. 
The allergen absorption through the intact mucosa and the interaction with local dendritic 
cells could switch on the process leading to immune-tolerance. In addition to the local effect, 
the swallowed allergen could induce a supplementary outcome based on a GALT-related 
mechanism (Akdis et al., 2001). In fact, the first method of sublingual administration of SIT, 
in which the allergen was spat out, was significantly less effective. Most of the 
immunological changes and mechanisms that occur with sublingual administration of high 
allergen dosage have been recently demonstrated (Moingeon et al., 2006).  
The aqueous extracts are highly effective, but induce more side-effects (local and systemic) 
than depot and modified vaccines (Larché et al., 2006). These have been developed in an 
attempt to reduce or remove allergenicity, while preserving or increasing the 
immunogenicity (Casanovas et al., 2005). Aqueous subcutaneous SIT is now the gold 
standard treatment for hymenoptera venom allergy and depot aeroallergen extracts for 
respiratory allergy (Wheeler & Woroniecki, 2004). The use of chemically modified allergens 
is not consensual. Although recent papers demonstrate a clinical benefit with allergoid 
therapy (Ibarrola et al., 2004), double blind placebo controlled studies comparing both 
extracts are still missing. On the other hand, the sublingual-swallowed administration of SIT 
in higher dosages had a clinical efficacy entirely demonstrated with similar immunological 
effects, namely the increase in allergen-blocking IgG, the induction of IgE-modulating CD8+ 
T cells, the reduction of mast cells and eosinophils on the target mucosa, the decrease in 
inflammatory mediators, and a modulation on the inflammatory trafficking cells by reduced 
expression of adhesion molecules (Bousquet, 2006). 
2. Kinetics of immunotherapy mechanism 
The studies on the dynamics of SIT are of extreme relevance, because they represent the 
only approach available to define, on a biological point of view, the mechanism by which 
the therapeutics works. Despite the current advances contributing to the wide knowledge of 
the modulator effect, these studies are extremely rare, as a result of several ethical, technical 
and economical boundaries. Furthermore, there are also several difficulties in transposing 
the results from experimental studies using laboratory animals to Humans.  
In a study using mice, the systemic activity of a modified aeroallergen, an allergoid 
administrated sublingually, was shown (Mistrello, 1994). However, before the study of an 
Italian group from Genoa in 1997, the kinetics and dynamics of the allergen in Humans was 
not known (Bagnasco, 1997). This study had the merit of assessing the response of the 
sublingual administration of a radioactively labeled allergen in a group of 9 healthy 
individuals (Bagnasco, 1997). Par j 1, the major Parietaria judaica allergen, was labeled with 
123I. In respect to the sublingual route, the application and deposition of the labeled allergen 
in 3 individuals was monitored for a period of 30 minutes before deglutition, by the 
acquisition of static images in the following 1, 2, 3, 5, 24 and 48 hours. In parallel, blood 
draws were collected for the determination of the radioactive counts at 5, 10, 20, 30 and 60 
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minutes, and then at 2, 3, 5 and 24 hours after the administration. A quantification of the 
same parameters in the urine was also performed. This study was able to demonstrate that 
the allergen was not degraded by the saliva and interestingly that there was no absorption 
by the sublingual mucosa. 
The plasma radioactive activity only occurs after the deglutition of the allergen. Another 
surprising fact is that an enormous radioactive activity of the labeled allergen in the sublingual 
region is still detected, even after 48hours and despite the deglutition. Furthermore, the study 
also compared the same methodology either with nasal and oral (immediate deglutition) 
administration. The results from the application of the allergen in a nasal pulverization 
demonstrated activity in the superior region of the pharynx and proximal esophagus, and 
persistence of the labeled allergen until 36hours, with no bronchial deposition, but having 
activity in the plasma since the beginning. The oral route is simultaneous to the detection of 
immediate activity in the plasma, characterized by a pick at 2hours, followed by a decline, but 
with no identification of the labeled allergen. Probably there is protein degradation and only 
small peptides are absorbed at the level on the intestinal mucosa. 
These results, done afterwards by the same group and obtained from healthy individuals, 
were crucial for the evaluation of the kinetics and dynamics of the allergen administration in 9 
allergic patients with rhinitis (Bagnasco, 2001). The study compared the different alternatives 
of sublingual administration of the Par j 1 allergen labeled with 123I. Namely non-modified 
allergen solution (drops), non-modified allergen in pills and modified allergen (allergoid) also 
in pills. The patients were monitored with dynamic acquisition in the first 20 minutes and 
static acquisitions of 5 minutes every hour until the 16th hour. Serial blood draws were also 
collected in order to quantify the radioactive plasmatic activity. The results confirmed 
persistent radioactive activity at the local of the administration of the allergen. For all the 
extracts, the plasmatic activity only occurs after deglutition. With the allergoid, the activity is 
higher, probably dependent of a lower enzymatic degradation and consequent lower 
possibility of intestinal absorption. The acquisitions in a gamma-rays camera only visualizes 
the activity after deglutition (1-5 minutes later), in the pharyngeal and esophagic region. 
The same group of investigators studied the kinetics of the intranasal administration of Par j 
1 labeled with 123I in a group of 3 patients with allergic rhinitis, using a similar methodology 
although with distinct time points (Passalacqua, 2005). The radioactive activity in the nasal 
region disappears rapidly in allergic patients when compared to healthy individuals. The 
clinic inflammation controlled by the administration of the therapeutic allergen in these 
patients may condition an increase in the depuration or clearance of the mucosa. Plasmatic 
activity is also observed after an effective deglutition of the allergen. Despite the reduced 
number of patients used to conducted this study, the results are significantly distinct from 
the results observed when using  the sublingual route, in which the radioactive activity 
persist at the local of administration, long after the deglutition of the therapeutic extract 
(Bagnasco, 2001).  
The same Italian group responsible for the study with allergens administrated by non-
injectable routes prompt the question of whether the results obtained up until that moment 
were restricted to specific characteristics of Parietaria judaica. Following this, the group 
published another study using a major allergen from Dermatophagoides pteronyssinus, the Der 
p 2 (Bagnasco, 2005). For the 7 patients with allergic rhinitis, the results were analogous to 
the ones mentioned above. This lead to the conclusion that the persistence of the radioactive 
activity at the local of administration of the allergen and the systemic absorption after the 
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deglutition is independent of the allergen used in the treatment and the chemical 
modification used. 
The studies regarding the kinetics and dynamics of immune-therapy administrated by non-
injectable routes were pioneer, even though its implementation was substantially more 
recent than conventional route, and interestingly they included the nasal route, which had 
no scientific validation for its efficacy (Bousquet, 1998; Alvarez-Cuesta, 2006). In respect to 
the subcutaneous route, our group has published in 2004 the first in vivo results regarding 
the dynamics of SIT in patients with allergic disease (Pereira, 2004). 
3. Dynamics of the immunotherapy mechanism 
The radioactive labeling of an allergen from the therapeutic extract is possible, but it would 
be restricted, exclusively, to one protein only. This could have been a strategy to evaluate 
the dynamics of the biological response to SIT. However, for patients under a maintenance 
treatment, the exclusion of some allergenic epitopes present in the therapeutic extracts 
would condition the interpretation of the results. Furthermore, it could, eventually, change 
the immunogenic structure of that epitope and as a consequence, the immune response that 
was induced. In these studies, the administration of the allergen extract, according to the 
maintenance scheme in place for each patient, would occur simultaneously with the 
reinjection of leucocytes labeled with 99mTc-HMPAO. The labeling of leucocytes with 99mTc-
HMPAO is a technique that, on the theoretical level, has affinity for all the cellular elements 
of the white series (mononuclear and polymorphonuclear) and all of these have a specific 
contribution in the inflammatory process (Kumar, 2005; Peters, 1986).  
The therapeutic allergenic extract injections always induce an inflammatory reaction at the 
local of the administration, detectable clinically by the presence of typical local signals. In 
the maintenance treatment, these symptoms have variable intensity and depend not only on 
the type of extract but also on the severity of the basal clinical features (Alvarez-Cuesta et 
al., 2006). The modified extracts and the extracts administrated sublingually are the ones 
that induce minor local secondary effects, as mentioned before. Therefore, although in a 
limited and controlled way, the SIT leads to an effective inflammatory allergic reaction in 
the area where the extract is applied, despite all the relevant immune-modulator 
mechanisms, which at the moment are well established for this therapeutic.  
This local inflammatory allergic reaction will be, presumably, responsible by the dynamics 
of a response highly similar to the one observed in the allergic response in general (Pereira, 
2009). Therefore, it can be admitted that the autologous reinjection of leucocytes will have a 
migration at that level by mechanisms dependent on the IgE-mediated mast cells activation 
(Bousquet, 1998; Alvarez-Cuesta et al., 2006). 
3.1 Patients studied 
Seventeen adult volunteer allergic patients were selected, 15 of them under maintenance 
therapeutic with specific immunotherapy. All were under a regular and programmed 
follow-up at the Immunoallergology department for the treatment of allergic pathology: 
respiratory allergy (bronchial asthma and rhinitis) and anaphylaxis (latex or hymenoptera 
venom). Until the date of selection of the patients, this treatment scheme has demonstrated 
clinical efficacy, translated by the complete remission of the symptoms, absent regular and 
preventive anti-allergic medication, no need of symptomatic medication in periods of 
worsening of the symptoms. Along with these criteria, it was also taken into account the 
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favorable evolution of the laboratory parameters, namely reduction of the cutaneous 
reactivity to the responsible allergen by allergic diathesis in cutaneous prick tests using 
standardized extracts, and the reduction in the levels of the serum specific IgE, relatively to 
the beginning of the treatment. For the study of the dynamics of this therapeutic, samples 
from patients using different routes of administration of SIT and different allergenic extracts 
were also included. Patients were selected according to the type of allergen extract and route 
of administration of the SIT (Table 1). 
 
Subcutaneous Administration Route 
 Aqueous subcutaneous extract (anaphylaxis) 
 4 patients: latex extract 
2 patients: Apis mellifera extract 
Subcutaneous depot extract (respiratory allergy) 
 2 patients: D pteronyssinus extract 
2 patients: pollen from Poaceae extract 
Subcutaneous modified allergen extract (respiratory allergy) 
 1 patient: pollen from Poaceae extract 
1 patient: pollen from Parietaria judaica extract 
Sublingual Administration Route (respiratory allergy) 
 2 patients: D pteronyssinus extract 
1 patient: pollen from Parietaria judaica extract 
Table 1. Patients under a specific immunotherapy treatment (extract, route of administration 
and allergic disease) 
The control group included 2 patients allergic to Dermatophagoides pteronyssinus, with 
asthma and rhinitis, non-submitted to SIT and controlled with daily inhaled corticotherapy 
(fluticasone furoate). None of the selected patients presented any other concomitant 
pathology, namely inflammatory, which could interfere with the interpretation of the 
results. Furthermore, neither of the patients was under any other medication, besides the 
ones mentioned. All female patients were submitted to a quick urinary test to exclude 
pregnancy. All the studies were conducted under strict hospital vigilance, and the day of the 
immunotherapy administration was exactly the one previously defined in the maintenance 
therapeutic scheme. This study was, obviously, submitted for the approval of the Ethics 
Committee of the Institution, according to the “Declaration of Helsinki” of the World 
Medical Association (Helsinki 1964; Tokyo 1975; Venice 1983; Hong-Kong 1989). 
3.2 Methodology for this study 
A standard technique was used for the labeling of circulating leucocytes with 99mTc-
HMPAO (Peters, 1986). 
The allergen extracts used in the patients with subcutaneous immunotherapy (aqueous and 
depot) or submitted to sublingual Dermatophagoides pteronyssinus treatment were produced 
by the ALK-Abelló Laboratory (Madrid, Spain). For another patient in SLIT, the Parietaria 
judaica extract was provided by the Stallergenes Laboratory (Paris-France). In respect to the 
SCIT with modified extracts (allergoid), the glutaraldehyde-modified extract from pollens of 
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Poaceae was supplied by BIAL-Aristegui Laboratory (Bilbao, Spain) and the Parietaria judaica 
extract modified by depigmentation was provided by the Leti Laboratory (Madrid, Spain).  
The maintenance dosage to which the patients were submitted on the day of the study 
corresponded to the one established on their treatment scheme, and was administrated on 
the pre-defined schedule. Two controls non-submitted to SIT with respiratory allergy to 
Dermatophagoides pteronyssinus were also studied. They were submitted, respectively to: 
-0,5cc of bacterial aqueous extract by the subcutaneous route, immune stimulant inductor of 
a IgG response (Ribomunyl ®, Pierre Fabre Médicament, France), containing ribosomal 
fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, 
Haemophilus influenzae and membrane fractions of Klebsiella pneumoniae. 
-0,5cc of phenolated aqueous solution administrated by the subcutaneous route, diluting the 
solution from the ALK-Abelló Laboratory (Madrid, Spain). 
Patients were positioned in dorsal decubitus, under a gamma camera. The puncture of the 
cubital vein with a caliber 14 catheter allowed the reinjection of the autologous leucocytes 
labeled with a radio-labeled pharmaceutical compound in fast bolus, followed by a venous 
wash with physiological serum. Simultaneously, the allergenic extract was administrated 
subcutaneously, according to the usual technique (Bousquet  et al., 1998)  in the external 
surface of the arm contralateral to the administration of the labeled cells. Both injections 
occurred at the same time, simultaneously to the beginning of the scintigraphic acquisition. 
The 3 allergic patients submitted to SLIT were placed in dorsal decubitus under a gamma-
rays camera, and drops containing the allergenic extract were administrated at the same 
time that the reinjection of radio labeled leucocytes in the cubital vein was performed. Three 
minutes later the allergen was swallowed, according to the usual protocol. 
For the control group, the subcutaneous administration of the saline solution and the 
bacterial extract were performed the same way as for the patients in the active group.  
In all the studies, the residual activity of the syringe containing the autologous cells that 
were reinjected was assessed, in order to quantify the radioactive dosage effectively 
administrated. The scintigraphic studies were performed under a gamma rays camera (GE 
XR, Milwaukee, USA) using a low energy and parallel cavities collimator coupled to a 
Camstar acquisition unity and to a eNTEGRA processing unity. The dynamic acquisition 
was obtained in an anterior side view of the head and neck to 64x64 resolution matrixes 
during 60 minutes (120 images x 30 seconds), followed by a static study at 60, 120, 180, 240, 
300 and 360 minutes after the administration of the allergen and leucocytes labeled with 
99mTc-HMPAO, during 5 minutes for each acquisition (256 x 256 resolution elements). The 
static images were obtained in anterior and posterior side views for the following 
projections: head and neck, thorax and abdomen. During the acquisitions, patients were 
asked to remain at rest, despite the induction of nasal symptoms, in order to maintain the 
geometry of the projections, and at the same time minimizing the distance to the detector. 
A qualitative evaluation of the images obtained in the dynamic acquisition was then 
performed, either by sequential analysis or using a video of 120 images. The moment in 
which the activity in the nasal region started was determined, as well as the local of the 
administration and the subsequent focalizations of the inflammatory activity that was 
induced. In the same way, a qualitative evaluation of the focalized inflammatory activity on 
defined timings for the static acquisition was performed. For the quantitative results, a 
different approach was chosen, in respect to the type of image in study. For the dynamic 
images obtained from the head and neck, the regions of interest were drawn (ROIs, region of 
interest) at the local of the administration of the allergen extract and /or controls, the 
background area (muscle) and also the following areas: oropharynx, cranial calotte and 
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cervical lateral-external region of the neck. The dynamic acquisition was obtained in 
anterior view of the thorax and neck for matrixes with a resolution of 64 x 64 elements, 
during 60 minutes (120 images x 30 seconds), followed by a static study at 60, 120, 180, 240, 
300 and 360 minutes for 5 minutes each acquisition (256 x 256 elements of resolution), after 
the administration of leucocytes labeled with 99mTc-HMPAO and the therapeutic allergen. 
The static images were obtained in anterior and posterior view for the thoracic projection 
and in anterior view for the abdominal projection.  
A qualitative study of the images obtained in dynamic acquisition was then conducted by a 
sequential analysis or in a video of 120 images. The moment of the beginning of the activity 
at the local of the administration of the extract and in subsequent focalizations of the 
inflammatory activity that was induced was then determined. In the same way, a qualitative 
evaluation of the inflammatory activity focalized at defined timings for the static acquisition 
was performed. For the quantitative analysis a different approach was taken, regarding the 
type of image in study. For the dynamic thoracic images, ROIs were draw at the local of 
administration of the allergen and/or controls, as well as in the background area (muscle) 
and in possible focalizations (cervical, armpit and thoracic). For each ROI the total values, 
the average per pixel and the maximum values were determined. The uptake coefficient 
(UC, uptake coefficient ROI) was then calculated as the ratio between the maximum 
measurements of each ROI and the average value in the background area. For a best 
accuracy of the results it was also calculated the corrected uptake coefficient (UCC, corrected 
uptake coefficient ROI) by subtracting the uptake coefficient ROI in the background from the 
uptake coefficient ROI for each of the areas analyzed. 
3.3 Results 
The qualitative and quantitative results from patients submitted to specific treatment will be 
presented. 
3.3.1 Qualitative results 
All images from patients submitted to SIT were interpreted by analyzing the images with 
the same color scale, Figure 1. These crescent colors (from black to white) translate the 
inflammatory activity induced by the therapeutic action. 
 
 
Fig. 1. Color scale from minimum activity (black) to maximum activity (white). 
The studies regarding each type of SIT in analysis, namely regarding the type of extract and 
route of administration, are presented here (Figures 2 – 7). Besides the static images for the 
acquisitions of the thoracic and abdominal side view of each of the exemplified patients, an 
image from the dynamic sequence corresponding to the time point in which the beginning 
of the anti-inflammatory activity is observed at the site of administration of the extract will 
be presented. Furthermore, images obtained from two control patients will also be 
presented, namely with administration of a saline phenolated solution (SS) and a bacterial 
extract (BE). In all the studies the hepatosplenic region should be considered as an image of 
subtraction that should not be taken into account or interpreted. The spleen since it 
sequesters labeled erythrocytes, even though at residual levels, but always present in the 
pellet of isolated cells; the liver because it represents the preferential location for 
metabolization of the radio labeled pharmaceutical compound. 
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Fig. 2. Scintigraphic study of patient C1, control, with respiratory allergy to Dermatophagoides 
pteronyssinus, submitted to subcutaneous injection with bacterial extracts. Panel A shows the 
beginning of the activity at the external side of the arm after 45 minutes. Panels B and C show, 
respectively, thoracic and abdominal static acquisitions, in an anterior view. 
For patient C1, submitted to subcutaneous injection with bacterial extract (BE), at 45 minutes 
we can observe inflammatory activity focalized at the site of administration. Furthermore, 
we observe focalizations, in the static studies, with inflammatory activity in bone structures 
(humeral head and iliac crest), as well as in the suprasternal region. The activity observed in 
the sternum and spinal cord (in anterior side view, not shown) should be interpreted with 
caution since there are superimposed structures with potential involvement. We do not 
observe intrapulmonary or intra-abdominal (intestinal) focalizations. 
Regarding patient C2, submitted to subcutaneous injection of phenolate saline solution (SS) 
in the external face of the right arm, we notice minimum activity 50 minutes after the 
injection. For the static acquisitions we also observe activity localized to the structures 
described.  
 
 
Fig. 3. Scintigraphic study of patient C2, control, with respiratory allergy to 
Dermatophagoides pteronyssinus, submitted to subcutaneous injection with phenolate saline 
solution. Panel A shows the beginning of the activity at the external side of the arm after 50 
minutes. Panel Panels B and C show, respectively, thoracic and abdominal static 
acquisitions, in an anterior view. 
www.intechopen.com
 Specific Immunotherapy and Central Immune System  
 
383 
 
Fig. 4. Scintigraphic study of patient 6 (anaphylaxis to Apis mellifera), submitted to 
subcutaneous injection with aqueous extract. Panel A shows the beginning of the activity at 
the external side of the arm after 35 minutes. Panel Panels B and C show, respectively, 
thoracic and abdominal static acquisitions, in an anterior view. 
For the patient (Figure 4), under treatment for anaphylaxis to hymenoptera venom, we 
observe inflammatory activity earlier at the local of administration of the therapeutic allergen 
extract, but the systemic involvement is also observed in all of the posterior scintigraphic 
images. Higher activity was detected in the bone structures, when compared to patient 3 with 
anaphylaxis to latex. We did not detect intra-abdominal (intestinal) focalizations in this 
patient. For these patients, as well as for all the other studies, the sternum bone structures and 
spinal cord will not be interpreted because of all the reasons already discussed. 
For the patient allergic to pollens (Figure 5), the beginning of the inflammatory activity was 
detected at 35 minutes on the site of administration of the therapeutic extract. A systemic 
involvement in all the acquisitions was observed. In the armpit homolateral to the injection 
of the extract, we detect activity that persists throughout the study, similar to what 
happened in the cervical-lateral region of the neck. In the intestinal area we only observe 
focalizations at 60 and 120 minutes. 
 
 
Fig. 5. Scintigraphic study of patient 8 with respiratory allergy (asthma and rhinitis) to grass 
pollen submitted to subcutaneous injection with depot extract. Panel A shows the beginning 
of the activity at the external side of the arm after 35 minutes. Panel Panels B and C show, 
respectively, thoracic and abdominal static acquisitions, in an anterior view. 
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For patient on figure 6, the inflammatory activity at the site of administration of the 
allergoid extract is highly reduced, when compared to the patients previously described. 
The systemic activity persists in all the structures considered, including the intra-abdominal 
area, from minute 60 to 120. 
 
 
Fig. 6. Scintigraphic study of patient 11 with respiratory allergy (asthma and rhinitis) to 
grass pollens, submitted to subcutaneous injection of a glutaraldehyde modified extract. 
Panel A shows the beginning of the activity at the external side of the arm after 50 minutes. 
Panel Panels B and C show, respectively, thoracic and abdominal static acquisitions, in an 
anterior view. 
The SLIT administration induced a very precocious beginning of activity when compared to 
the subcutaneous route. Patient from Figure 7, submitted to treatment with D pt extract, the 
inflammatory activity in the oropharynx occurred 3 minutes after the administration of the 
drop extract. We also observed a more relevant involvement of the cervical-lateral structures 
of the neck, which persisted throughout the trial. The systemic involvement was also present 
in this patient in different structures: intrapulmonary, bones and suprasternal region. 
 
 
Fig. 7. Scintigraphic study of patient 13, with respiratory allergy (asthma and rhinitis) to 
Dermatophagoides pteronyssinus, submitted to sublingual administration. Panel A shows the 
beginning of the activity in the oral region after 3 minutes. Panel Panels B and C show, 
respectively, thoracic and abdominal static acquisitions, in an anterior view. 
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3.3.2 Quantitative analysis 
All the scintigraphic studies were submitted to a quantitative evaluation in order to 
determine the corrected uptake coefficients. ROIs were draw in the areas with focalized 
activity, which included: local of administration of the allergenic extract, suprasternal 
region, humerus head and iliac crest. Besides this, every time intra-abdominal (intestinal) 
focalizations were present, the respective UCCs were calculated. Naturally, for each 
projection a ROI in the muscle area was draw, representing the background area.  
 
 
Fig. 8. Corrected uptake coefficients in the region of the administration of the allergenic 
therapeutic extract for the subcutaneous injectable treatments (1. Dynamic; 2. Static) 
throughout the study (expressed in minutes). A: aqueous extracts; B: depot extracts; C: 
chemically modified extracts (allergoid). 
The beginning of the inflammatory activity for patients submitted to SCIT was different 
between the groups of patients in this study. The aqueous extracts for the treatment of 
anaphylaxis were the ones that induced higher UCCs, both in the dynamic and static 
evaluations. However, for the same type of extract, it seems that there are no relevant 
differences in respect to the type of allergen in the treatment, Figure 8. 
Patients under treatment with the depot extracts showed intermediate levels between 
patients with aqueous extracts and allergoid. However, we should emphasize that a patient 
under depot extracts to dust mites showed a highly reduced UCC at the spot of the 
therapeutic injection, as well as a patient under treatment with pollinic extract modified 
with glutaraldehyde. The control patient submitted to BE, showed very significant UCCs at 
the local of administration in the evaluations made after the first 60 minutes. On the other 
side, for the patient submitted to SS, the quantification of the activity at the local of injection 
persisted always in much reduced levels.  
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For patients submitted to treatment with SLIT, the inflammatory activity is detected very 
early in the process, and persists throughout time at relatively constant levels, Figure 9. The 
patients allergic to dust mites showed higher levels when compared to the patient allergic to 
Parietaria judaica. However, for this patient, the study took place during the pollinic period, 
and therefore a reduced therapeutic dosage was administrated, which can justify, 
eventually, the results obtained.  
 
 
Fig. 9. Corrected uptake coefficients in the region of the administration of the sublingual 
allergenic therapeutic extract throughout the study (expressed in minutes). 1. Dynamic; 2. 
Static 
The area located above the sternal furcula presented an early inflammatory activity, even 
during the dynamic studies. Since this region includes an extremely rich set of vascular 
structures, the effect of leukocyte recirculation maintained in the beginning of the study 
cannot be excluded. Therefore, it was decided to only evaluate the coefficients acquired with 
the static studies, Figure 10. Globally, the results are substantially higher than the control 
patient submitted to SS injection. Furthermore, it was also observed a slow increase during 
the experiment. 
 
 
 
Fig. 10. Corrected uptake coefficients, taken at different time points during the experiment 
(minutes), obtained in the suprasternal region after the administration of the therapeutic 
extract. A: aqueous extracts; B: depot extracts; C: chemically modified extracts (allergoid); D: 
sublingual extracts 
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The evaluation of the UCCs in the bone structures localized in the humeral head and iliac 
crest was then performed, exclusively for static acquisitions, Figure 11. 
 
 
 
 
Fig. 11. Corrected uptake coefficients, taken at different time points during the experiment 
(minutes), obtained in the iliac crest after the administration of the therapeutic extract. A: 
aqueous extracts; B: depot extracts; C; chemically modified extracts (allergoid); D: 
sublingual extracts 
The coefficients obtained in the two bone structures were similar and, globally, there was an 
apparent progressive increase throughout the experiment. However, regarding the type of 
extract and the method of administration, there wasn’t a characteristic profile of the 
inflammatory activity in these structures. For the motives previously expressed, no other 
bone focalizations were considered. 
 
 
 
 
Fig. 12. Comparative results of the UCC obtained for the suprasternal of patients submitted 
to aqueous extracts (SCIT1) for the treatment of anaphylaxis; depot and allergoid extracts 
(SCIT2) for the treatment of respiratory allergy and sublingual aqueous extracts (SLIT), also 
for the treatment of respiratory allergy. The results obtained for control patients submitted 
to injection of bacterial extract (BE) or phenolated saline solution (SS). For all patients, 
samples were collected at 60, 180 and 360 minutes. 
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Fig. 13. Comparative results of the UCC obtained for the iliac crest of patients submitted to 
aqueous extracts (SCIT1) for the treatment of anaphylaxis; depot and alergoids extracts 
(SCIT2) for the treatment of respiratory allergy and sublingual aqueous extracts (SLIT), also 
for the treatment of respiratory allergy. The results obtained for control patients submitted 
to injection of bacterial extract (BE) or phenolated saline solution (SS). For all patients, 
samples were collected at 60, 180 and 360 minutes. 
In the inflammatory focalization dependent of the ROI from the suprasternal region, no 
prevalence for a type of extract or method of administration of the treatment seems to exist, 
Figure 12. Similarly, it can be observed an increase in UCCs throughout the experiment. The 
same considerations can be applied to the inflammatory activity induced in the iliac crest, 
Figure 13. 
3.4 Discussion 
The administration of an allergenic therapeutical extract induces, always, an inflammatory 
reaction at the administration site that is characterized by the presence of clinically validated 
local symptoms. The modified extracts and the extracts delivered sublingually are the ones 
that induced lower secondary effects, as previously described. Although the main 
immunomodulator mechanism is already well established in SIT, it can dictate, in a limited 
and controlled approach, the effective inflammatory allergic reaction at the administration site. 
Therefore, we can admit that the autologous reinjection of leucocytes will have a migration 
dependent of the mast cell activation mediated by IgE (Togias, 2004; Kelly, 2007). This local 
inflammatory allergic reaction is, presumably, responsible for the dynamics of a response 
similar to allergy. Regarding the lymphocyte population, the circulatory migration to the 
tissue where the specific allergic reaction took place, is mediated by the expression of 
specific adhesion molecules that specify the type of cell implicated in the migration to the 
tissue (Togias, 2004). The migration of Th2 cells is associated to the expression of VCAM-1 
and P-selectin, under effect of IL-4 and IL-13, that depends on the activation of lymphocyte 
transduction signals by transcription factors similar to STAT6 (Lukacs, 2000). On the other 
hand, the migration of Th1 cells seems to be dependent on the expression of STAT4, due to 
the effect of IL-12, and associated to the RANTES and ICAM-1 mechanism. In an interesting 
study with intradermic injection of allergenic peptides without the ability to induce an IgE 
response, it was possible to observe lymphocyte trafficking from the vascular department 
(Haselden, 1999). Also, the intervention of T-reg cell in the mechanisms of 
immunomodulation of SIT are well established either by inducing the population of Th1 
cells or reducing the number of Th2 (Woodfolk, 2007; Francis, 2003). 
Nevertheless, in these cells, it is not clear which is the specificity towards the allergen or 
what is the eligibility of the method of the induction (systemic or inhaled). Furthermore, it 
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was also not clear what is the dosage required for induction or what type of regulatory cells 
are induced (natural T-reg produced by the thymus and with an effect dependent of cellular 
contact or adaptive T-reg cells induced on the periphery and with the effect dependent of 
IL-10 or TGF-ǃ) (Woodfolk, 2007). At the same time, other lymphocytes, such as CD8+ e 
NKT cells, have the ability to respond to the allergen and represent other vectors involved in 
the SIT mechanisms (Woodfolk, 2007, Agea, 2005)). 
As previously mentioned, DCs are considered central cells in inflammation and immune 
tolerance often reported in the SIT mechanisms. These cells represent the antigen presenting 
cells (APC) that, after migrating to the regional lymph node, induce an effective and 
differentiated immune response. Nevertheless, this is a very heterogeneous and diversified 
population, ubiquitously present, although in a reduced number when compared to other 
resident or circulation populations (von Bubnoff, 2002; Novak, 2004). Furthermore, it is 
known that myeloid DC cells can migrate from the blood to the tissues in order to capture 
antigens (Novak, 2004; Schmit-Weber, 2002, Allam, 2003). In specific situations, and under 
appropriated stimulus, the peripheral monocytes can differentiate into myeloid DC (von 
Bubnoff, 2002). 
The skin and sublingual mucosa are, naturally, distinct. Therefore the mechanisms derived 
from the administration of the therapeutical allergenic extract should reflect this difference. 
The Langerhans cell (LC) is a DC myeloid cell (DC1) and are the most representative APCs 
in the skin. After a correct local stimulus, the monocyte chemotactic protein (MCP) 
determines the recruitment of LC progenitors from the bone marrow to the skin and the 
subsequent migration to the peripheral lymph nodes (Novak, 2004). The DC in the oral 
mucosa presents differences relatively to the skin, namely it expresses a higher number of 
MHCI and MCHII molecules, as well as the co-stimulation molecules CD40, CD80 and 
CD86 and also more FcǄRIII (CD16), FcǄRI (CD64) and FcεRI receptors (Allam, 2003). 
Several lymphoid structures are present in the oropharynx: tonsils, lymphatic ganglions and 
diffuse lymphoid tissue (Bienestock, 2005). It is well established that plasmacytoid DCs 
(DC2) are the APC most abundant in the Waldeyer’s tonsillar ring and in the ganglion areas 
dependent on T cells, but that these cells are unable to effectively internalize the antigen 
(Novak, 2004). This is surely, a biologic characteristic of this region with consequences on 
the immune response on this area. 
The subcutaneous tissue is, undoubtedly, composed by a population of resident cells that 
are biologically less active that the ones present in the oral mucosa. Nevertheless, the 
therapeutical administration of allergenic extracts by both ways has proven to be effective 
and able to induce an immunomodulator response in patients of IgE mediated allergy. This 
project did not intended to validate the efficacy of this therapy, broadly documented, but to 
study the dynamic of the resulting mechanism due to the administration of the therapeutical 
extract in patients maintained in the previously determined individual dosage. 
Theoretically, it would be extremely relevant to have monitored, under the same 
methodology, this treatment in different periods throughout the year, but the radioactive 
dosage accumulated would be ethically unacceptable. 
In patients under subcutaneous injectable treatment, the anaphylaxis treatment with 
aqueous extracts induced the fastest signs of inflammatory activity in the administration 
site. The activity became visible 35 minutes after the administration, while with depot 
extracts, the activity was only visible between 40 and 45 minutes after the administration. In 
all patients, an increase in the intensity of the activities was observed throughout the 
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observation period. The higher activity induced by the aqueous extracts did not translate 
into more exuberant clinical signs. The patients in SCIT to latex presented local clinical signs 
more pronounced than two patients allergic to Apis. In these two patients, the inflammatory 
activity was bigger and deeper, which can be explained by a higher amount of protein and 
the volume of extract administered. 
In patients with respiratory allergy submitted to SCIT with depot extracts there were no 
evident differences connected to the extract composition, either mites or pollens. 
Regarding the allergoid extracts, a reduced inflammatory activity was observed at the 
administration site, similarly to what was previously reported in the literature and 
demonstrated in daily clinical practice (Casanovas et al., 2005, 2007; Ariano et al., 1999). The 
modification of the allergenic with glutaraldehyde reduced the local inflammatory activity 
to levels similar to the ones observed in the control patients submitted to SS. In patient C1, 
asthmatic allergic to dust mites submitted to subcutaneous injection with BE, a local 
inflammatory activity was observed 45 minutes after the administration. This is an extract 
with immunomodulator activity, which induces the response of an IgG polyclonal antibody 
well documented in the literature (Clot, 1997). Although the local demonstration of activity 
was expected, the time necessary to observe activity was also extremely reduced. 
The patient submitted to a phenolated solution presented a minimal local inflammatory 
activity only seen 60 minutes after the subcutaneous injection. Similarly to the patients 
studied in the previous chapter, it is considered that the irritation potential of this 
preservative can justify this result (Spiller et al., 1993). 
In this study it was possible to assess and confirm the dynamics of the inflammation 
induced by the subcutaneous application of an allergenic extract. These results, although not 
surprising, were not unequivocally demonstrated, namely in terms of extension, depth of 
the adjacent region or evolution of the reaction along the course of the experiment. One 
advantage of the depot extracts when compared to the aqueous extracts, besides the safety 
profile, was the slower release of the allergenic protein (Wheeler & Woroniecki, 2004). In our 
patients we clearly observed a lower activity of these extracts, despite the fact that the 
patients with the aqueous extracts presented a worse level of basal allergic disease. The 
lymphocyte traffic seemed to be more intense and persistent with these extracts since the 
soluble allergenic is more readily available. In all patients submitted to SCIT, it is possible to 
observe systemic focalizations before the locally induced inflammatory activity. In the 
dynamic acquisition during the first 60 minutes, the anterior thoracic projection only 
permits to infer the potential activity in this view. In the intramedullary area of the humeral 
head is evident a significant intensity, surely dependent on the recirculation of cells 
representing all leukocyte cell populations. 
In patients submitted to SCIT, the activity in bone structures and in thymic tissue presented 
a very intense activity that increased throughout the experiment. It should be noticed that 
these structures anatomically overlap to other organs from the central immune systems, but 
that in the peripheral immune lymphoid system, such as regional ganglion, and presumably 
in the region of the mediastinum, there is also evidence of activity. Furthermore, the mucosa 
immune system seems to be involved namely the pulmonary and less consistently the 
intestinal. The early involvement of the central lymphoid structures was an unexpected 
event, but was very consistent in all patients. 
Obviously, with the methodology used it is not possible to determine the cell type and 
profile that is responsible by the activity induced by the migration from the circulation to a 
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specific focalization. Nevertheless, given the actual knowledge regarding the mechanism 
that modulate this therapeutic, it is possible to admit that a diversified set of cells with 
different activation profiles and with divergent implications in the different structures. 
The subcutaneous administration of the allergenic extract, particularly with aqueous 
extracts, defines an evident local inflammatory process. To this level, we admit that some 
conjunctive mast cells can be activated, although with limited intensity. As described in the 
literature, we also admit that the presence of conjunctive DCs, with IgE receptors, can favor 
this type of reaction. However, the most likely mechanism can depend on an effective 
presentation of the allergen to presenting cells and posterior migration to local-regional 
structures. This mechanism could explain the ganglion activity observed in the homolateral 
arm, with the involvement of other ganglion structures more distant, such as the ones 
present in the cervical lateral-external area. 
On the other hand, we admit the influx from the circulation of DC or monocytes into the site of 
administration of the allergenic extract, since it is well known the ability of these cells to 
maturate into DCs or phagocytes. This dual mechanism, that simultaneously induce a 
biological defense from the aggression and favors an effective immune response, are probable 
local mechanisms. Therefore, the local administration of therapeutical allergens limits the local 
response that rapidly seems to have local-regional and systemic consequences. Probably, not 
only the biologic mediator produced in situ, as well as the following cell migration, 
presumably DCs, and the cellular limitations in venular structures in the proximity of the 
allergenic, allow the amplification of the systemic effect by mechanisms, possibly similar to the 
ones verified in the allergic reaction (Togias, 2004; Kelly, 2007). 
The qualitative analysis of our SCIT patients corroborates, although indirectly, the 
complexity of the tolerance mechanisms, well described in the literature. The anatomic 
involvement of structures implicated with organs of the central immune system seems to 
sustain these effects. The activity observed in the bone marrow areas allow us to speculate 
that it could limit the modification of cellular profiles, namely lymphocyte, that has been 
documented in these patients (Denburg et al., 2000). Also, the demonstration of the 
contribution of regulatory cells can be sustained by our results given the involvement of the 
anatomic region reported to the thymic tissue, whose function persists throughout life 
(Arellano et al., 2006). Nevertheless, the pace of this process and the systemic involvement, 
evidenced by the focalization of the inflammatory activity, is clearly higher than expected, 
given the present knowledge. It should be noticed that this dynamic study evaluates, in a 
certain way, the biologic response in the whole organism. This contrasts with the usage of 
small biologic samples (such as tissues or humors), a procedure that is very common in most 
clinical and experimental studies. 
We admit that the lungs are involved in the influx of leukocytes to the BALT, but it should 
be noticed that this is a preponderant location for the clinical symptoms that lead to 
treatment in patients with respiratory allergy. 
In patients in SLIT, the beginning of the inflammatory activity in the site of administration 
was substantially earlier than the observed in patients in SCIT. In the two patients allergic to 
mites and in the patient allergic to Parietaria judaica, the activity was noticed 3 and 5 minutes 
after the respective induction. Despite this early onset of activity, no substantial differences 
were registered when the final results were compared, namely in the effects of regional or 
distant structures. 
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In fact, it seems evident that since the administration of the extract, a continuous increase of 
the local inflammatory activity as well as in cervical structures, particularly in the cervical 
lateral-external region. As described previously for SCIT patients, the venous recirculation 
at very early stages does not allow an effective validation of this effect, but the assessment in 
later periods, both in the dynamic or static acquisitions, there is an evident focalization in 
these cervical structures. For these patients, and with exception of the patient injected with 
extract modified with glutaraldehyde, and using the color scale, the intensity of the 
oropharynx is clearly inferior than the one verified in the injection site. Other clear 
difference, is the absence of a progressive increase of the inflammatory response focalized at 
the administration site verified in subsequent static evaluations. However, the systemic 
effect is very similar to the observed in patients under injectable treatment. We observe 
pulmonary focalizations as well as in regions reported to the organs from the immune 
central system. In these regions, the areas reported to the bones and in suprasternal, the 
images from the static studies support an increase of activity throughout the experiment. 
In patients under SLIT, the extract was swallowed 3 minutes after the administration. It 
would be expected an intra-abdominal involvement, with intestinal focalizations. However, 
in none of these 3 patients that effect was observed. We admit that the extract can be 
completely degraded in the stomach, which would prevent an effect in the intestinal 
mucosa. Our results seem to corroborate the therapeutic inefficiency of the oral 
immunotherapy, which is not scientifically validated by the literature (Bousquet et al., 1998). 
It is not possible to define and characterize the migrating population that focalizes in the 
distinct structures in patients under SLIT. Despite this, the available scientific knowledge 
allows us to assume that the allergenic persistence in the sublingual mucosa, as previously 
demonstrated (Bagnasco et al., 2005), allows the induction of the following immune 
response. As previously described, abundant lymphoid structures with specific biologic 
characteristics are present in this mucosa. The DC permits a fast transport to the tonsils and 
lymphatic ganglions in a magnitude that cannot be compared to the subcutaneous tissue. 
However, it is well established that the majority of DCs present in the tonsils are DC-2. 
These cells do not have the capacity to effectively internalize the allergenic protein and 
efficiently present it to the T-cell. Therefore, and although in smaller numbers, the DC-1 cells 
probably have a preponderant function. As a result, we admit that there might be an influx 
from the circulation of DC and monocytes, and that these, once in the mucosa, will 
differentiate and maturate. The early start of the activity will, presumably, result from the 
presence and availability of a biologically more active and diversified resident population. 
The reduced population of mast cells in the oral mucosa limits the local inflammatory 
response when compared to the subcutaneous administration. Therefore, and in theory, we 
can predict that the resulting mechanism derives from the activation of DCs and the 
presentation to lymphocytes in structures in the oral mucosa and that are dependent from 
the immune system. Thus, the therapeutical extract produces a powerful stimulus that 
initiates a local and systemic immune response, surely by regulating biologic mediators of 
cytokines and chemokines, as well as by limiting the entry of circulating cells from the 
vascular-lymphoid structures present in the oral mucosa. 
The systemic effects in areas of the central immune system, similarly to what was observed 
for the injectable extracts, can corroborate the tolerance and immunomodulation, presently 
well documented in the therapeutical intervention. 
In patients under injectable therapy, the UCCs results obtained in the homolateral armpit 
are higher that was expected by the exclusive visualization of the scintigraphic images. We 
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admit that the results obtained in this focalization are, eventually, due to the migration of 
lymphatic cells from the administration site of the therapeutical extract to the ganglion 
structures present in the armpit region that allow a therapeutical amplification with natural 
systemic effect. In fact, functional studies in melanoma using a radio-labeled pharmaceutical 
compound administered intradermally evidenced the high rate of lymphatic migration to 
distant ganglion structures (Alazraki et al., 2002). Since the most important ganglion 
structures of the subcutaneous cellular tissue of the arm are located in the armpit, that the 
effective presentation of the allergenic protein to the T-cell in the lymph node is mediated by 
the DC and that the intralymphatic migration is very fast, the UCCs obtained in our patients 
are, probably, justified. 
The eventual lymphatic migration proportions, are in fact, an amplification of the immune 
mechanism with characteristics that clearly favors tolerance. Therefore, it could lead not 
only to an effective diffusion of the response throughout the immune-lymphoid system, as 
well as a recirculation of cells from the allergenic administration site to distant central 
structures and organs that can allow the synergistic effects that concur with the 
immunomodulation of this therapy. 
Therefore, the presumed ascending drainage justifies the precocious and persistent UCCs 
induced by the subcutaneous administration of the allergen in other vascular-lymphatic 
structures, anatomically located in the lateral-external region of the neck. Eventually, this 
process allows an amplification of the response to cervical structures with high biological 
activity. To this level, we do not observe significant differences of UCCs due to usage of 
different injectable extracts. 
Although we verify focalization in the pulmonary region throughout the dynamic 
acquisition, we only calculated the coefficients in the static acquisition. The intense venous 
recirculation of leukocytes after the reinjection could falsify the results. However, all our 
patients presented intrapulmonary activity. Particularly in patients undergoing treatment 
for respiratory allergy, the influx of these cells to the targeted organ is compatible to the 
methods sensitivity. This way, the recirculation of leukocytes between the vascular 
compartment and the mucosa of the different organs of the immune system allow the 
convenient organic homeostasis that justifies the reduced numbers of pulmonary UCCs 
verified in control patients. 
Given the results obtained in the patient submitted to BE, we presume that the unspecific 
bacterial immunomodulators have, besides favoring an IgG polyclonal response, a more 
central and selective regulator effect than the one presumed until now, but for which the 
clinically efficacy has been shown (Bousquet & Fiocchi, 2006). Regarding the patient allergic 
to dust mites submitted to SS injection, the reduced UCCs values were consistent 
throughout the experiment, and we presume that are derived from the organic recirculation 
of leukocytes, and correspond to the basal function of this tissue 
The activity observed in the bone structures was confirmed by the UCCs calculated in the 
two considered ROIs. There were no differences in the results obtained in the medullary 
area of the humeral head or the iliac crest. 
Our results suggest that either the bone marrow or the functional thymic tissue, organs from 
the central immune system, are preferential targets of the induction mechanism of SCIT, 
regardless of the type of allergenic extract. It should be noticed that in patients treated with 
modified extracts, allergoid, the dosage of allergenic used was substantially higher than the 
dosages in the depot extracts, and that the UCCs obtained in the regions associated with 
bone marrow were also higher. However, the size of the sample does not allow us to 
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conclude if this treatment is more selective or effective. Nevertheless, we presume that given 
the previously described mechanisms, the bone marrow may participate in the SIT 
mechanism since earlier stages, right after the injection of the extracts. 
In the suprasternal region, the UCCs were very similar in the different groups under active 
treatment and significantly distinct from the ones obtained in the patient submitted to SS 
injection. This data corroborates the eventual physiological dynamic of the leukocytes, 
possibly dependent of the persistent limitation of the medulla, even in cells apparently 
mature that were collected from the venous compartment. 
In the intra-abdominal region, the UCCs obtained in the intestinal focalizations, observed 
occasionally in the scintigraphic images, confirmed the involvement of this mucosa. The 
calculations were only performed in focalizations areas during the first 4 hours, in order to 
minimize interferences due to faecal elimination. 
For the three patients under sublingual treatment we do not have a control that we can 
compare to. Despite this, the values obtained in the asthma and rhinitis patients allergic to 
dust mites submitted to BE or SS in the nasal region (see previous chapter), are similar to the 
type of response verified in SLIT patients.  
The capture and the inflammatory activity on the site of the administration of the 
therapeutic extract evidenced a very precocious activity that subdue in relatively high 
values throughout the experiment. These results are consistent with previously described 
dynamic studies (Bagnasco et al., 2005). The quantitative analysis does not evidence an 
increase of the local activity as seen in the majority of patients submitted to injectable 
extracts. In this mucosa, the presence of mast cells is extremely reduced which, despite the 
persistence of the extract (even after it was swallowed), does not induce a broader influx of 
circulating leukocytes due to this mechanism. Therefore, we presume that the much more 
limited activity observed can be due to circulating DCs and mast cells that have a 
recognized ability to mature and differentiate in the offended tissues. The readily 
availability of immune-lymphoid tissue in this localization will allow a fast amplification 
and dissemination of cells with the ability to induce an immunomodulator mechanism. 
In patient 15, submitted to sublingual treatment with Parietaria judaica extracts, the UCCs 
obtained throughout the observation period were the lowest in these three patients. In fact, 
since the test was conducted during the pollinic period, we established a reduction of the 
allergenic dosage during the pollination period of this herb. It is a clinical procedure well 
established in the therapeutic with injectable extracts, although not consensual in sublingual 
treatment (Bousquet, 2006; Bousquet et al., 1998). Despite this, and since this patient lives in 
a geographic area with high levels of aeropalinologics, it was decided to reduce the 
maintenance dosage to 2/3 (10:15 drops). Eventually, this procedure had implications in the 
type of response that was evidenced, not only in the local activity as well as in the distant 
focalizations. 
In patients under SLIT treatment, the UCCs obtained in the structures localized in the 
lateral-external region of the neck confirmed the analytic results from the scintigraphic 
images. The apparent descendent drainage in these vascular-lymphatic systems 
corroborates our proposal, particularly in the intrapulmonary capture. In the anatomic 
regions reported to the organs of the central immune system we observed UCCs with 
similar behavior than those verified in the patients under injectable treatment. Therefore, we 
presume that in SLIT there is also an early participation of the bone marrow and the 
functional thymic tissue. 
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4. Involvement of the organs from the immune system 
In SCIT, we admit that the APC migration to ganglion structures is determinant to obtain a 
systemic effect and to acquire an immunomodulator and/or tolerance state. In patients 
submitted to SLIT, the inflammatory activity was observed in the first minutes, much earlier 
but with clearly lower gradients throughout the experiment. As previously described, the 
morphological characteristics of the conjunctive subcutaneous tissue and the oral, in 
particular from the sublingual region, are completely distinct. Therefore, the local 
availability of the whole array of the adjacent immuno-lymphatic-ganglion structures allows 
the effectiveness of the early stages of the mechanism. Paradoxically, the characteristics of 
the DCs present in the oral mucosa, mainly from the plasmacytoid type, are responsible for 
a less effective response (Novak et al., 2004). Previous work evidenced the presence of the 
allergenic extract in the sublingual mucosa long after it was swallowed, but it was extremely 
reduced 24 hours after that administration (Bagnasco et al., 2005). This difference, relatively 
to the subcutaneous administration, has natural implications in the periodicity of the 
therapeutical application. The amplification of the systemic effect seems to result from a 
descending involvement of structures presumably vascular-lymphatic in the lateral-external 
of the neck by a mechanism similar to SCIT. 
Given the differences between the two administration methods and the type of therapeutic 
extract, the results obtained suggest a potentially selective influx of cells from the 
mononuclear-phagocyte system to the deposition site, similarly to the allergic reaction, 
which was documented in an interesting study done in ten patients submitted to an inhaled 
aggression (Upham et al., 2002). Naturally, the mediators produced locally will have a 
potential modulator effect in the adjacent vascular endothelium, which allows a possible 
immunomodulator effect in circulating leukocytes that allows a systemic involvement. 
The recirculation and following focalization of intrapulmonary leukocytes was observed in 
all patients. The presence of the bronchus-associated lymphoid tissue (BALT) supports these 
results, in particular since this mucosa is a potential target in patients undergoing treatment 
of respiratory allergy. However, regarding the involvement of the intestinal mucosa, where 
the gut associated lymphoid tissue (GALT) is located, focalization of the inflammatory 
activity was occasionally observed. The SLIT with allergenic deglutition three minutes after 
the deposition did not produced any additional gain. In fact, we admit that the protein 
degradation can occur as result of the gastric enzymatic degradation as proposed in the 
literature (Bousquet et al., 1998). 
The lymphocyte cellular modulation from a mainly Th2 profile into a lymphocyte profile 
mostly Th1, as well as the induction of T-lymphocytes with regulatory characteristics, are 
the most studied and documented mechanisms in the literature (Larché et al., 2006; Till et 
al., 2004; Canonica & Passalacqua, 2003). The complexity of the processes involved allows a 
constant effect throughout the treatment, but its dynamic mechanism is not well established. 
The need to extend in time the specific treatment translates the need to promote an 
immunologic memory status. The patients studied in this project were well documented, 
both clinically and laboratorial, and all were in maintenance treatment. Although we know 
several mechanisms involved, it is not known the dynamics and the regions implicated after 
the administration of the extract, nor in the induction stages or in maintenance periods. 
It seems obvious the involvement of organs from the central immune system in the SIT 
action mechanisms. It also appears, given the results obtained in allergic patients submitted 
to specific provocation, that the participation of these organs could have a dynamic and 
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pace with similar magnitude. These results look as redundant or expectable, but we had no 
previous knowledge about the location and timing of the immunomodulation process that 
has been so well characterized in the laboratory. 
The induction of medullar cellular clones with phenotypes that favor the secretion type Th1 or 
clones precursors of DCs with tolerogenic characteristics are events that sustain the activity of 
the bone marrow, and is present at an early stage in patients undergoing treatment (van 
Helvoort et al., 2004; Moingeon et al., 2006). The essential function of several regulatory T-cells, 
well placed and with central function in the SIT mechanism, is an element that supports not 
only the intervention of bone marrow as well as the thymic activity (Schmidt-Weber & Blaser, 
2005; Moingeon et al., 2006). Despite the anatomic involution, the organic function persists in 
adulthood (Hakim et al., 2005; Harris et al., 2005; Arellano et al., 2006). In this regard, we 
should notice that in one patient we had the opportunity to acquire a scintigraphic 21 hours 
after the simultaneous administration of leukocytes labeled with 99mTc-HMPAO and allergenic 
aqueous latex extract. In this patient we observe the persistence of the inflammatory activity in 
both the suprasternal and bone medullar areas, Figure 14. 
It should be noticed that the half-life of the radio-labeled compound is 6 hours, and 
therefore the acquisition occurred at a time well past its half life. Nevertheless, the activity 
persisted at the administration site, allowing the therapeutic effect to continue, as well as 
activity in intra-bone areas and in the suprasternal region, which we judge representative 
the functional thymic tissue. 
The study in this patient was done occasionally and was, in fact, a surprise, revealing 
activity that we supposed it was not possible due the anatomic physical conditionings. We 
proceeded with the quantitative evaluation that unequivocally contributed the qualitative 
assessment done in this patient. In Figure 15 we show the UCCs obtained for this patient 
after 6 hours (last programmed observation that coincides with 99mTc half-life) and 21 hours. 
Although the UCCs are lower after 21 hours when compared to the values obtained after 6 
hours, it is evident that, despite after nearly four half-lives, the activity reported is very 
significant. We should highlight that the UCC in the ROI draw in the homolateral armpit 
maintains constant values of activity, which supports a continuous involvement. 
The study in this patient, since it is not likely a continuous recirculation of leukocytes 
without focalization and influx to this organ, allows us to deduce that we were able to 
obtain an image of the functional thymic tissue.  
Our results support the research developed since 1985 by a Canadian group that sustains 
the involvement of the central immune system’s organs, mainly bone marrow, in the 
pathophysiology of the allergic inflammation (Denburg et al., 1998). The results obtained in 
experimental models and in humans with allergy are essential, regarding the participation 
of hematopoietic mechanisms during the response to an allergenic (Denburg et al., 1998; 
Denburg & van Eeden, 2006, Sehmi et al., 1996; Cyr & Denburg, 2001). 
In a comparative study with 153 patients with pollinic rhinoconjunctivitis, the effect of the 
administration of SIT either subcutaneously or intralymphatic was compared (Senti et al., 
2008). In the later group, the administration of the pollinic allergen directly in a inguinal 
lymphatic ganglion using ultrasound as a control, with only three injections separated by 4 
weeks, in the response to a specific nasal induction 4 months after the last administration, 
required a dosage ten times higher than the one required in patients under SCIT treatment 
for three years and with a cumulative dosage drastically higher and with multiple allergenic 
injections. In addition to the clinical efficacy, the adverse effects were neglectable and the 
lymphatic intraganglionic injection was very well tolerated. This promising and innovative 
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study can induce a complete reversion on the treatment of IgE mediated allergy. It should 
be noted that these results were obtained with conventional allergens. However we consider 
that the future use of highly selective peptides directly administered in immune structures 
can induce an even more elective therapeutical effect. 
 
 
Fig. 14. Scintigraphic study in patient with anaphylaxis to latex, submitted to subcutaneous 
aqueous extract. Static acquisitions, anterior thoracic (A) and abdominal (B) views, 21 hours 
after the beginning of the study. 
 
 
Fig. 15. Corrected uptake coefficient obtained in static acquisitions after 6 and 21 hours in 
different locations in patient with the diagnosis of latex anaphylaxis submitted to 
subcutaneous aqueous extract treatment. 
5. Final remarks 
SCIT limits the visualization of the inflammatory activity in systemic focalizations earlier 
than at the site of the extract administration. Generically, the local inflammatory activity 
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evolves throughout time and is significantly broader than the one verified in the clinic, by 
the observation of the inflammatory signals. The pollinic extract modified with 
glutaraldehyde does not present nearly any inflammation at the injection site. 
The involvement of the armpit’s region homolateral to the administration of the extract 
occurs very early, which is compatible with the focalization of the inflammatory activity in 
immune ganglia structures. We admit an ascending drainage effect from the site of the 
extract’s administration. 
In patients submitted to SLIT, the visualization of the inflammatory activity is evident three 
minutes after the therapeutical extract’s administration. In contrast to what was observed in 
SCIT patients, the inflammatory intensity, in the focalization, is relatively constant during 
the observation period, without an increase in later acquisitions. The SLIT also produced a 
very early systemic effect, namely with activity in the lateral-cervical region, where the 
presence of vascular-lymphatic structures have been reported. We admit that there is a 
descending drainage effect from the site of the extract’s administration. 
 
 
Fig. 16. Local and systemic events related to specific immunotherapy (A: subcutaneous; B: 
sublingual) 
The visualization of the activity with intra-abdominal (intestinal) focalization was 
occasional, but exclusive to patients in SCIT. In patients undergoing SLIT, despite the 
swallowing of the extract, there was no focalization in this area three minutes after the 
extract’s administration, Figure 16. 
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The anatomic regions reported to the central immune system (bone marrow and 
suprasternal area) evidenced a constant growth in UCCs during the experiment. The SIT 
triggers an early and continuous influx of leukocytes, from the circulation into the central 
immune organs, with potential implications in the immunomodulatory mechanism.  
Regarding the response’s magnitude in the bone marrow and functional thymic tissue, there 
were no apparent differences regarding the type of extract and the administration type 
during the first six hours after the administration of the therapeutical extract. 
The persistence of the therapeutical extract administered subcutaneously indicates an 
inflammatory activity and a continuous influx of inflammatory cells. In the sublingual 
administration, the influx and local activity are lower, without any evidence of an increase 
in the inflammatory activity throughout the experiment. Therefore, patients under SLIT 
treatment will require administrations more frequent and with shorter breaks between 
administration in order to obtain a persistent therapeutic effect. 
Our results reinforce the need for new and elective pharmacologic investigation strategies, 
focusing on the mainstay function of the central immune organs in the treatment of systemic 
inflammatory disease such as allergy. In fact, in face of the current knowledge of the 
immunological effects induced by SIT, namely the effect on T-regs with a long-lasting 
biological effect, this would only be possible if a central immune cellular modulation had 
occurred. 
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